Table 1

Key baseline characteristics for the ITT population

All participants≥75 years old
Characteristic≥75 years old<75 years oldSitagliptinPlacebo
(n = 2,004)(n = 12,347)(n = 970)(n = 1,034)
Male sex1,356 (67.7)8,847 (71.7)682 (70.3)674 (65.2)
Age (years)78.3 ± 3.163.4 ± 6.478.3 ± 3.078.4 ± 3.2
BMI (kg/m2)*28.9 ± 4.830.3 ± 5.729.0 ± 4.928.9 ± 4.8
Systolic blood pressure (mmHg)*137 ± 18134 ± 17137 ± 18137 ± 18
Diastolic blood pressure (mmHg)*74 ± 1178 ± 1074 ± 1174 ± 11
HbA1c (%)*7.18 ± 0.467.24 ± 0.487.19 ± 0.467.17 ± 0.46
HbA1c (mmol/mol)*55.0 ± 5.155.7 ± 5.255.1 ± 5.154.8 ± 5.0
eGFR (mL/min/1.73 m2)*65.5 ± 19.276.3 ± 21.065.3 ± 19.065.7 ± 19.3
 ≥90205 (10.3)3,026 (24.8)95 (9.9)110 (10.8)
 60–89963 (48.6)6,761 (55.3)474 (49.4)489 (47.8)
 30–59814 (41.0)2,437 (19.9)390 (40.6)424 (41.4)
 <301 (0.1)2 (<0.1)1 (<1.0)0
LDL cholesterol (mmol/L)*2.3 ± 2.62.4 ± 1.22.4 ± 3.72.2 ± 0.9
Median duration of diabetes, years (IQR)*12 (7, 21)9 (5, 15)13 (7, 21)12 (7, 21)
Prior heart failure*422 (21.1)1,970 (16.0)190 (19.6)232 (22.4)
Medication use
 Metformin*1,449 (72.3)10,265 (83.1)711 (73.3)738 (71.4)
 Sulfonylurea946 (47.2)5,569 (45.1)442 (45.6)504 (48.7)
 Insulin501 (25.0)2,844 (23.0)255 (35.6)246 (33.8)
 Median daily dose, units (IQR)51.0 (34.0, 80.0)44.0 (28.0, 67.5)44.0 (28.0, 72.0)42.0 (28.5, 64.0)
 Monotherapy for type 2 diabetes*1,066 (53.2)5,755 (46.6)514 (53.0)552 (53.4)
 Dual combination therapy for type 2 diabetes*913 (45.6)6,477 (52.5)446 (46.0)467 (45.2)
 Aspirin*1,473 (73.5)9,829 (79.6)702 (72.4)771 (74.6)
 Any antiplatelet*1,591 (79.4)10,443 (84.6)771 (79.5)820 (79.3)
 Statin1,582 (78.9)9,998 (81.0)761 (78.5)821 (79.4)
 Any lipid lowering1,641 (81.9)10,340 (83.7)797 (82.2)844 (81.6)
  • Data are n (%) or mean ± SD, except where indicated. P values comparing sitagliptin and placebo groups were not calculated. See Supplementary Table 2 for full list of baseline characteristics.

  • *P values <0.0001 comparing older to younger cohorts.